Effects of tumor necrosis factor, endothelin and nitric oxide on hyperdynamic circulation of rats with acute and chronic portal hypertension

Ji-Jian Wang, Gen-Wu Gao, Ren-Zhong Gao, Chang-An Liu, Xiong Ding, Zhen-Xiang Yao

METHODS: Chronic portal hypertension was induced in Wistar rats by injection of carbon tetrachloride. After two weeks of cirrhosis formation, L-NMMA (25 mg/kg) was injected into one group of cirrhotic rats via femoral vein and the experiment was begun immediately. Another group of cirrhotic rats was injected with anti-rat TNFα (300 mg/kg) via abdominal cavity twice within 48 h and the experiment was performed 24 h after the second injection. The blood concentrations of TNFα, ET-1 and NO in portal vein and the nitric oxide synthase (NOS) activity in hepatic tissue were determined pre-and post-injection of anti-rat TNFα or L-NMMA. Stroke volume (SV), cardiac output (CO), superior mesenteric artery blood flow (SMA flow) and iliac artery blood flow (IAflow) were measured simultaneously. Acute portal hypertension was established in Wistar rats by partial portal-vein ligation (PVL). The parameters mentioned above were determined at 0.5 h, 24 h, 48 h, 72 h and 120 h after PVL. After the formation of stable PHT, the PVL rats were injected with anti-rat TNFα or L-NMMA according to different groups, the parameters mentioned above were also determined.

RESULTS: In cirrhotic rats, the blood levels of TNFα, NO in portal vein and the liver NOS activity were significantly increased (P<0.05) while the blood level of ET-1 was not significantly changed. PP, SV, CO, SMAflow and IAflow were ameliorated. After injection of L-NMMA, the blood level of NO and the liver NOS activity were recovered to those of the controls. PP and CO were also recovered to those of the controls. SV, SMAflow and IAflow were ameliorated. In PVL rats, the blood levels of TNFα, NO in portal vein and the liver NOS activity were gradually increased and reached the highest levels at 48 h after PVL. The blood level of ET-1 among different staged animals was not significantly different from the control animals. PP among different staged animals (2.4±0.18 kPa at 0.5 h, 1.56±0.08 kPa at 24 h, 1.74±0.1 kPa at 48 h, 2.38±0.05 kPa at 72 h, 2.39±0.16 kPa at 120 h) was significantly higher than that in controls (0.9±0.16 kPa). After injection of anti-rat TNFα in 72 h PVL rats, the blood level of TNFα was lower than that in controls (14±14 pg/mL vs. 48.87±32.79 pg/mL). The blood level of NO and the liver NOS activity were significantly decreased, but still higher than those of the controls. The blood level of ET-1 was not significantly changed. PP was decreased from 2.38±0.05 kPa to 1.68±0.12 kPa, but significantly higher than that in controls. SV, CO, SMAflow and IAflow were ameliorated. After injection of L-NMMA in 72 h PVL rats, the blood level of NO and the liver NOS activity were recovered to those of the controls. PP, SV, CO, SMAflow and IAflow were also recovered to those of the controls.

CONCLUSION: NO plays a critical role in the development and maintenance of HC in acute PHT and is a key factor for maintenance of HC in chronic PHT. TNFα may not participate in the hemodynamic changes of HC directly, while play an indirect role by inducing the production of NO through activating NOS. NO evidence that circulating ET-1 plays a role in both models of portal hypertension has been found.

INTRODUCTION

Associated with hyperdynamic circulatory syndrome (HCS), the portal hypertension (PHT) is characterized by systemic vasodilatation, increase of plasma volume, cardiac output and regional blood flow[1,8]. Although it is most likely initiated by vasodilatation resulted from an increase of vasodilator activity[9], the etiology of HCS is still controversial. Two potent vasodilators, endogenous nitric oxide (NO) and tumor necrosis factor (TNF) may play important roles in the pathogenesis of hemodynamic changes of PHT[1,10]. As a powerful vasocostructor, endothelin (ET) could influence the

BASIC RESEARCH

Abstract

AIM: To evaluate the effect of tumor necrosis factor (TNF), endothelin (ET) and nitric oxide (NO) on hyperdynamic circulation (HC) of rats with acute and chronic portal hypertension (PHT).

METHODS: Chronic portal hypertension was induced in Wistar rats by injection of carbon tetrachloride. After two weeks of cirrhosis formation, L-NMMA (25 mg/kg) was injected into one group of cirrhotic rats via femoral vein and the experiment was begun immediately. Another group of cirrhotic rats was injected with anti-rat TNFα (300 mg/kg) via abdominal cavity twice within 48 h and the experiment was performed 24 h after the second injection. The blood concentrations of TNFα, ET-1 and NO in portal vein and the nitric oxide synthase (NOS) activity in hepatic tissue were determined pre-and post-injection of anti-rat TNFα or L-NMMA. Stroke volume (SV), cardiac output (CO), superior mesenteric artery blood flow (SMA flow) and iliac artery blood flow (IAflow) were measured simultaneously. Acute portal hypertension was established in Wistar rats by partial portal-vein ligation (PVL). The parameters mentioned above were determined at 0.5 h, 24 h, 48 h, 72 h and 120 h after PVL. After the formation of stable PHT, the PVL rats were injected with anti-rat TNFα or L-NMMA according to different groups, the parameters mentioned above were also determined.

RESULTS: In cirrhotic rats, the blood levels of TNFα, NO in portal vein and the liver NOS activity were significantly increased (P<0.05) while the blood level of ET-1 was not statistically different (P>0.05) from the control animals (477.67±38.81 pg/mL vs 48.87±32.79 pg/mL, 278.41±20.11 µmol/L vs 113.28±14.51 µmol/L, 1.81±0.06 u/mg prot vs 0.87±0.03 u/mg prot and 14.33±4.42 pg/mL vs 8.72±0.79 pg/mL, respectively). After injection of anti-rat TNFα, the blood level of TNFα was lower than that in controls (15.17±18.79 pg/mL vs 48.87±32.79 pg/mL). The blood level of NO and the liver NOS activity were significantly decreased, but still higher than those of the controls. The blood level of ET-1 was not significantly changed. PP, SV, CO, SMAflow and IAflow were ameliorated. After injection of L-NMMA in 72 h PVL rats, the blood level of NO and the liver NOS activity were recovered to those of the controls. PP and CO were also recovered to those of the controls. SV, SMAflow and IAflow were ameliorated. In PVL rats, the blood levels of TNFα, NO in portal vein and the liver NOS activity were gradually increased and reached the highest levels at 48 h after PVL. The blood level of ET-1 among different staged animals was not significantly different from the control animals. PP among different staged animals (2.4±0.18 kPa at 0.5 h, 1.56±0.08 kPa at 24 h, 1.74±0.1 kPa at 48 h, 2.38±0.05 kPa at 72 h, 2.39±0.16 kPa at 120 h) was significantly higher than that in controls (0.9±0.16 kPa).

CONCLUSION: NO plays a critical role in the development and maintenance of HC in acute PHT and is a key factor for maintenance of HC in chronic PHT. TNFα may not participate in the hemodynamic changes of HC directly, while play an indirect role by inducing the production of NO through activating NOS. NO evidence that circulating ET-1 plays a role in both models of portal hypertension has been found.

Wang JJ, Gao GW, Gao RZ, Liu CA, Ding X, Yao ZX. Effects of tumor necrosis factor, endothelin and nitric oxide on hyperdynamic circulation of rats with acute and chronic portal hypertension. World J Gastroenterol 2004; 10(5): 689-693
pathogenesis of hemodynamic changes of PHT as well[5,11-15]. Since ET has contradictory effect on blood vessels in comparison with the former two, it is hard to imagine that they synergistically take part in the hemodynamic changes. It is thus necessary to find out what kind of role the three factors play in the pathogenesis of HCS, respectively.

MATERIALS AND METHODS

Reagents
Carbon tetrachloride was purchased from Chongqinq Chemical Reagents Factory (Chongqing, China). A rabbit anti-rat TNFα antibody was purchased from PharMingen Company (USA). N\(^{-}\)-methyl-L-arginine (L-NMMA) and endothelin EIA kit were purchased from Cayman Company (USA). Rat TNFα ELISA kit was purchased from Endogen Company (USA). NO and NOS determining kits were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China).

Animal model of acute PHT (aPHT)
Partial portal vein ligation (PVL) was performed to establish the aPHT model as described previously[16]. In brief, male Wistar rats (220-280 g, offered by the Animal Center of Chongqing University of Medical Sciences) had free access to water and standard rat chow. After fasted overnight, the rats were anesthetized with pentobarbital intra-abdominally at a dose of 60 mg/kg. The portal vein was isolated and two ligatures were placed around both the portal vein and a 16-gauge blunt-end needle. One ligature was placed 1 mm distal to the bifurcation of portal vein and the other ligature was placed 1-2 mm to the input point of splenic vein. The needle was ligated together with the portal vein and immediately removed to allow the portal vein to expand to the limit imposed by the ligature. The abdomen was closed. In sham-operated rats, surgery consisted of dissection and visual inspection of the portal vein without ligation.

Animal model of chronic PHT (cPHT)
Carbon tetrachloride induced cirrhosis was made as the cPHT model. Male Wistar rats (150-200 g, provided by the Animal Center of Chongqing University of Medical Sciences) had free access to standard rat chow and 100 mL/L alcohol. Cirrhosis model was established by injection with 600 mL/L carbon tetrachloride mixed with paraffin liquid subcutaneously at a dose of 0.3 mL/100g at the lateral abdomen of both sides, twice a week for 17 times. The rats were allowed to stabilize for 2 weeks.

Determination of hemodynamic indexes

Stroke volume (SV) and cardiac output (CO) Ultrasound probe of HEWLETT PACKARD 5500 type ultrasonic instrument (USA) was placed on the parasternum of rats at the left ventricle long axis and mitral valve level and then exchanged by M type ultrasonic image. The inner computer system of this instrument would calculate and display the data we needed.

Superior mesenteric artery (SMA) and iliac artery (IA) blood flow SMA and IA were isolated and embraced by a cuff of electromagnetic flowmeter (NIHON KOHDEN, Japan) respectively. Its blood flow was determined while blood passed a photoelectric sensor.

Portal pressure (PP) and right atrial pressure (RAP) A 7 gauge needle was penetrated into portal vein in the direction of liver and a catheter was inserted through the internal jugular vein into the right atrium and connected to a pressure transducer respectively. PP and RAP were recorded with a four-channel physiometer (NIHON KOHDEN, Japan).

Mean arterial pressure (MAP) Rat’s tail was placed in a photoelectric channel and MAP was determined with an RBP-1 type blood pressometer.

Calculation of superior mesenteric artery vascular resistance (VR\(_{SMA}\)) and iliac artery vascular resistance (VR\(_{IA}\)). VR\(_{SMA}\) and VR\(_{IA}\) were calculated according to the following formula reported by Colombato et al[9].

\[
\text{VR}_{SMA}(\text{kPa}/\text{L} \cdot \text{min}) = \frac{\text{MAP} - \text{PP}}{\text{SMA-flow}}
\]

\[
\text{VR}_{IA}(\text{kPa}/\text{L} \cdot \text{min}) = \frac{\text{MAP} - \text{RAP}}{\text{IA-flow}}
\]

Serum levels of TNFα, ET-1 and NO and hepatic activity of NOS
Blood was obtained from the portal vein at the time of sacrifice. Hepatic tissue was obtained from the left lobe of rat’s liver. Serum level of TNFα was measured by ELISA according to the manufacturer’s instructions (Phar Mingen Co., USA). Serum samples were analyzed for ET-1 content by EIA according to the manufacturer’s instructions (Cayman Co., USA). Serum samples and hepatic tissues were analyzed for NO content and NOS activity according to the manufacturer’s instructions by Nanjing Jiancheng Bioengineering Institute (Nanjing, China).

Experimental protocol
The rats involved in this experiment were divided into experimental group, treated group and control group. Fifty aPHT rats were divided into five staged subgroups (0.5 h, 24 h, 48 h, 72 h and 120 h after PVL, 10 rats each group) and 10 cPHT rats were used as the experimental group. Twenty cPHT rats and 20 aPHT rats were divided into two groups (10 rats each group) respectively as the treatment group, and the method of treatment was as following. Ten cPHT rats were injected with anti-rat TNFα twice within 48 h and the experiment was performed 24 h after the second injection and 10 aPHT rats were injected with anti-rat TNFα at 0.5 h and 48 h after PVL respectively and the experiment was performed at 72 h after PVL (one dose of 300 μg/kg, via intra-abdominal cavity). The other 10 aPHT rats and 10 cPHT rats were injected with L-NMMA (25 mg/kg) through femoral vein 72 h after PVL and the experiment was performed immediately. Ten normal rats and 10 sham operated rats were used as the cPHT and the aPHT control groups respectively. The following parameters were determined, namely the hemodynamic indexes, serum levels of TNFα, ET-1 and NO, hepatic NOS activity.

Statistical analysis
Data were expressed as means±SD and analysis of variance was performed using SPSS 8.0 software. Differences between groups were analyzed using t-test. One-way analysis of variance was used for multiple comparisons, and Newman-Keuls test was used for intra-group comparisons. P<0.05 was considered statistically significant.

RESULTS

Hemodynamic change
In PVL rats, SV, CO, PP, SMAflow and IAnflow were significantly increased from 0.16±0.04 mL/s, 0.058±0.008 L/min, 0.9±0.16 kPa, 8.24±1.16 mL·min\(^{-1}\) and 10±0.89 mL·min\(^{-1}\) to 0.27±0.02 mL/s, 0.113±0.004 L/min, 1.74±0.1 kPa, 17.58±0.7 mL/min and 20.42±1.07 mL/min respectively at 48 h after PVL (P<0.05). VR\(_{SMA}\) and VR\(_{IA}\) were significantly decreased from 15.57±2.75 kPa/L·min and 13.58±2.19 kPa/L·min to 5.96±0.35 kPa/L·min and 5.62±0.33 kPa/L·min respectively at 48 h after PVL (P<0.05).
These hemodynamic variables no matter increased or decreased, all reached a maximal level at 72 h after PVL (P<0.05) and did not change thereafter (P>0.05). In cirrhotic rats, SV, CO, PP, SMAflow and IAflow were significantly increased from 0.162±0.04 mL/s, 0.058±0.017 L/min, 0.91±0.16 kPa, 8.42±1.16 mL/min and 10±0.89 mL/min to 0.57±0.06 mL/s, 0.159±0.031 L/min, 2.26±0.39 kPa, 27±1.19 mL/min and 27.33±1.21 mL/min respectively at the time of cirrhosis formation (P<0.05). VRalpha and VRdelta were significantly decreased from 15.57±2.74 kPa/ml/min and 13.58±2.19 kPa/ml/min to 4.07±0.43 kPa/ml/min and 4.44±0.13 kPa/ml/min respectively at the time of cirrhosis formation (P<0.05).

**Alteration of serum TNFalpha, ET-1 and NO and hepatic NOS activity**

Serum TNFalpha and NO levels and NOS activity were significantly increased at 24 h compared with those of control (P<0.05) and reached a maximal level at 48 h after PVL and did not change thereafter. An increase of serum ET-1 levels was also observed at different time points post PVL, however, all of them did not reach the significant level as compared with control (P>0.05). The serum TNFalpha and NO levels were significantly increased compared with control in cirrhotic rats (P<0.05) and their increment was markedly greater than those rats 48 h after PVL (P<0.05). The NOS activity was also markedly increased (P<0.05) and the serum ET-1 level was slightly increased, but did not reach the significant level (P>0.05) compared with control in cirrhotic rats (Table 1).

**Effects of anti-rat TNFalpha and L-NMMA on serum TNFalpha, ET-1 and NO and hepatic NOS**

The serum level of TNFalpha was markedly decreased and lower than that of controls in both rat models, and the serum level of NO and hepatic NOS activity were significantly decreased, but still markedly greater than those of controls. Injection of anti-TNFalpha had no effect on the level of ET-1. The serum level of NO and hepatic NOS activity were significantly decreased to the levels of the controls in both rat models after injection of L-NMMA (Table 2).

### Table 1: Serum levels of TNFalpha, ET-1 and NO and hepatic NOS activities in PVL and cPHT rats

| Groups          | TNFalpha (pg/min) | ET-1 (pg/min) | NO (µmol/L) | NOS (u/mg prot) |
|-----------------|-------------------|---------------|-------------|-----------------|
| Control         | 48.67±32.79       | 8.72±0.79     | 113±15      | 0.9±0.03       |
| cPHT            | 477.67±83.84      | 14.33±5.44    | 278.41±20.11 | 1.6±0.06      |
| cPHT+anti-rat TNFalpha | 15.17±18.79     | 14.33±4.42    | 190.61±10.9  | 1.39±0.04     |
| cPHT-L-NMMA     | —                 | —             | —           | —              |
| PVL72 h         | 416±48           | 13.1±3.2      | 215.49±12.75 | 1.67±0.16     |
| PVL72 h+anti-rat TNFalpha | 14±14        | 13.5±2.6      | 178.59±14.61 | 1.34±0.09     |
| PVL72 h+L-NMMA  | —                 | —             | 104.6±18    | 0.95±0.08      |

**Effects of anti-rat TNFalpha and L-NMMA on hemodynamic variables**

In both rat models, SV, CO, PP, SMAflow and IAflow were significantly decreased, but were still markedly higher than those of the controls. However, VRalpha and VRdelta were significantly increased but still markedly lower than those of the controls after injection of anti-TNFalpha. In PVL rats, SV, CO, PP, SMAflow, IAflow, VRalpha and VRdelta were all recovered to the levels of the controls after injection of L-NMMA. In cPHT rats, CO and PP were exclusively recovered to the levels of controls. SV, SMAflow, IAflow, VRalpha and VRdelta were markedly increased or decreased, but still significantly different from those of the controls after injection of L-NMMA (Table 3).

### Table 2: Effects of anti-rat TNFalpha and L-NMMA on levels of TNFalpha, ET-1 and NO and NOS activity in PVL and cPHT rats

| Groups          | TNFalpha (pg/ml) | ET-1 (pg/ml) | NO (µmol/L) | NOS (u/mg prot) |
|-----------------|------------------|--------------|-------------|-----------------|
| Control         | 48.67±32.79      | 8.72±0.79    | 113±15      | 0.9±0.03       |
| cPHT            | 477.67±83.84     | 14.33±5.44   | 278.41±20.11 | 1.6±0.06      |
| cPHT+anti-rat TNFalpha | 15.17±18.79    | 14.33±4.42   | 190.61±10.9 | 1.39±0.04     |
| cPHT-L-NMMA     | —                | —            | —           | —              |
| PVL72 h         | 416±48          | 13.1±3.2     | 215.49±12.75 | 1.67±0.16     |
| PVL72 h+anti-rat TNFalpha | 14±14       | 13.5±2.6     | 178.59±14.61 | 1.34±0.09     |
| PVL72 h+L-NMMA  | —                | —            | 104.6±18    | 0.95±0.08      |

### Table 3: Effects of anti-rat TNFalpha and L-NMMA on hemodynamic variables

| Groups          | SV (ml/s) | CO (l/min) | PP (kPa) | SMAflow (l/min) | IAflow (kPa·l/min) | VRalpha (kPa·l/min) | VRdelta (kPa·l/min) |
|-----------------|-----------|------------|----------|-----------------|--------------------|---------------------|---------------------|
| Control         | 0.162±0.04 | 0.05±0.017 | 0.91±0.16 | 8.42±1.16      | 10±0.89            | 15.57±2.74          | 13.58±2.19          |
| cPHT            | 0.59±0.06  | 0.159±0.031 | 2.26±0.34 | 27±3.19        | 273.33±21.11      | 4.07±0.43           | 4.44±0.51           |
| cPHT+anti-rat TNFalpha | 0.39±0.08  | 0.138±0.029 | 1.53±0.13 | 20.75±1.92     | 24.15±1.67        | 5.56±0.59           | 5.21±0.51           |
| cPHT-L-NMMA     | 0.32±0.02  | 0.076±0.005 | 1.12±0.08 | 17.12±0.82     | 16.08±0.74        | 10.13±0.26          | 8.84±0.66           |
| PVL72 h         | 0.24±0.04  | 0.072±0.013 | 0.85±0.15 | 9.82±0.96      | 10.77±1.11        | 12.58±0.93          | 12.42±0.99          |
| PVL72 h+anti-rat TNFalpha | 0.24±0.04  | 0.072±0.013 | 0.85±0.15 | 9.82±0.96      | 10.77±1.11        | 12.58±0.93          | 12.42±0.99          |
| PVL72 h+L-NMMA  | 0.24±0.04  | 0.072±0.013 | 0.85±0.15 | 9.82±0.96      | 10.77±1.11        | 12.58±0.93          | 12.42±0.99          |
DISCUSSION

In our study, HCS was observed in rats with acute and chronic PHT, and characterized by the increase of SV, CO, regional blood flow and PP, as well as the decrease of peripheral and splanchnic vascular resistance. This agreed with a lot of literature[1-8]. Lopez-Talavera et al[9,10] studied the correlation between hemodynamic changes and TNFα on days 5, 13 and 14 after PVL, and found that TNFα might play a role in HCS of portal hypertension. In this study, we found that the serum level of TNFα in portal vein was markedly increased at 24 h, reached a peak at 48 h and maintained stable thereafter in PVL rats. Whereas, the obvious hemodynamic changes occurred at 48 h and HCS was induced at 72 h, about 24 h later than the obvious increase in TNFα level. The serum level of TNFα was much more higher in cPHT rats than in rats 48 h after PVL. There was no obvious difference between the hemodynamic indexes of both groups. Therefore, we speculated that TNFα might play a role in the early stage of HCS, and that overproduction of TNFα might have a mild effect on hemodynamic changes. In the anti-rat TNFα experiment, we found that the serum level of TNFα was lower than that of the controls and the effect of TNFα was completely inhibited by the injected anti-rat TNFα. Although the hemodynamics was significantly changed, it still had a remarkable difference in comparison with the controls. In other words, HCS was improved and a new HCS balanced on a lower basis formed. At the same time, the NO levels and hepatic NOS activity in rats with hepatic cirrhosis and PVL were decreased by 20-25% and 15-30%, respectively. Kaviani et al[11] revealed that after gastric strips from PVL rats were incubated with TNFα neutralizing antibody, inducible NOS mRNA expression was significantly decreased by 40%, 70%, and 80% after 1, 2, and 6 h. This suggested that the vasoactive effect of TNFα itself on the development and formation of HCS in portal hypertension was little, and that corresponding hemodynamic changes after injection of TNFα antibody were due to the elimination of TNFα activation on NOS and the decreased production of NO. This conclusion disagreed with the report of Lopez-Talavera et al[12] that anti-rat TNFα treatment of rats after PVL significantly inhibited hyperdynamic circulation and reduced portal pressure. It was also inconsistent with the report of Munoz et al[13]. In their experiment, anti-TNFα polyclonal antibodies were injected into rats before and 4 days after portal vein stenosis (PVS) (short-term inhibition) and at 24 h and 4, 7, 10 day after PVS (long-term inhibition). After a short-term inhibition or a long-term inhibition, portal pressure kept unchanged. Tabrizchi[14] found that cardiac output, blood pressure and mean circulatory filling pressure were significantly reduced, but the arterial resistance increased following treatment with TNFα in anaesthetized rats. This, obviously, did not accord with the features of HCS at PHT, and also suggested that TNFα did not directly take part in the hemodynamic changes at PHT.

In our study, we found the serum NO level and hepatic NOS activity in the two animal models with portal hypertension were decreased by 20-25% and 15-30% respectively after injection of anti-rat TNFα antibody. This suggested that the increase of serum NO level was stimulated by the combination of TNFα and other media such as IL-6 and INFα etc., which agreed with what was reported[15,16,21]. Wiest et al[21] reported that upregulation of eNOS release and increase of NO by SMA endothelium occurred before the development of hyperdynamic splanchnic circulation, suggesting a primary role of NO in the pathogenesis of arterial vasodilatation. But the results reported by Alborno et al[22] disagreed with those of ours. Their results showed that dexamethasone (an inhibitor of the expression of the iNOS) administration did not modify systemic and splanchnic hemodynamic parameters in endotoxemic cirrhotic rats and suggested that stimulation of iNOS might not play a role in increasing NO production in portal hypertension. We found that the NO level in portal vein and the liver NOS activity were significantly decreased at the level of controls by injecting L-NMMA in cirrhotic rats and in rats 72 h after PVL. In PVL rats, the hemodynamics was recovered to the controls. In cirrhotic rats, the PP was also recovered to the control. But the SV was still significantly greater than that of control and the systemic vasodilation was not recovered to the state of control. These results suggested that NO played a critical role in the development and maintenance of HCS in acute PHT and was a key factor in maintenance of HCS in chronic PHT. This conclusion was consistent with those of most authors[15,17-22,29]. In patients with chronic portal vein hypertension, since the tissue structure of vascular wall was changed due to the long term dilatation of systemic blood vessels, the dilated blood vessels would be hard to recover, even if the effect of vasodilators had been completely eliminated.

Elevated ET-1 level in blood and its active role in portal hypertension in cirrhotic patients and a variety of animal models have been reported by many authors[13,14,16,17-20]. Nevertheless, Poo et al[30] reported that the liver paracrine ET system did not play a major role in the pathogenesis of portal hypertension, but took part in the development of liver fibrogenesis. Varagic et al[31] reported that circulating endothelin-1 did not play a role in spontaneously hypertensive rats. In this study, the blood level of ET-1 in portal vein was mildly increased but not significantly higher in comparison with the controls in cirrhotic and PVL rats. This finding suggested that ET-1 might not play a role in the development of hemodynamic abnormalities in PHT. It might keep the tension of blood vessels and antagonize the effect of vasodilators. Therefore, ET-1 may have a regulating effect on the vasodilatation and vascular refilling. Our finding was consistent with Poo et al[30], but inconsistent with the other authors[12,15,17-20].

Based on the result of a combination study of TNFα, NO and ET, we draw a conclusion that TNFα may not directly participate in the hemodynamic changes of HCS, while exert an indirect effect by inducing the production of NO. NO is the primary factor for forming and maintaining HCS at PHT. ET does not directly take part in the hemodynamic changes of PHT either, while keeps the tension of blood vessel and prevents it from overdilatation under the effect of vasodilatation factors.

REFERENCES

1. Huang YQ, Xiao SD, Zhang DZ, Mo JZ. Nitric oxide synthase distribution in esophageal mucosa and hemodynamic changes in rats with cirrhosis. World J Gastroenterol 1999; 5: 213-216
2. Treviisani F, Sica G, Mainqup S, Santese G, Notariris SD, Caraceni P, Domenicali M, Zaca F, Grazi GL, Mazzotti A, Cavallari A, Bernardi M. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology 1999; 30: 1387-1392
3. Zhu JY, Leng XS, Wang D, Du RY. Effects of somatostatin on hemodynamics in cirrhotic patients with portal hypertension. World J Gastroenterol 2000; 6: 143-144
4. Lebrec D, Moreau R. Pathogenesis of portal hypertension. Eur J Gastroenterol Hepatol 2001; 13: 309-311
5. Tsugawa K, Hashizume M, Migo S, Kishiha F, Kawaha H, Tomikawa M, Tanoue K, Sugimachi K. Role of nitric oxide and endothelin-1 in a portal hypertensive rat model. Scand J Gastroenterol 2000; 35: 1097-1105
6. Howe LM, Boothe DM, Slater MR, Boothe HW, Wilkie S. Nitric oxide generation in a rat model of acute portal hypertension. Am J Vet Res 2000; 61: 1173-1177
7. Bi XJ, Chen MH, Wang JH, Chen J. Effect of endotoxin on portal hemodynamic in rats. World J Gastroenterol 2002; 8: 528-530
Moller S, Bendtsen F, Henriksen JH. Splanchnic and systemic hemodynamic derangement in decompensated cirrhosis. Can J Gastroenterol 2001; 15: 94-106

Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor α: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995; 108: 761-767

Lopez-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszmann RJ. Thalidomide inhibits tumor necrosis factor α, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. H epatology 1996; 23: 1616-1621

Liu F, Li JX, Li CM, Leng XS. Plasma endothelin in patients with endotoxemia and dynamic comparison between vasoconstrictor and vasodilator in cirrhotic patients. World J Gastroenterol 2001; 7: 126-127

Chen CC, Wang SS, Lee FY, Chang FY, Lin HC, Chu CJ, Chen CT, Huang HC, Lee SD. Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats. Hepatology 2001; 33: 816-820

Nagase N, Dhra DK, Yamanai A, Emi Y, Udagawa J, Yamamoto A, Tachibana M, Kubota H, Kohno H, Harada T. Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. Hepatology 2000; 31: 1107-1114

Gottardi AD, Shaw S, Sagner H, Reichen J. Type A, but not type B, endothelin receptor antagonists significantly decrease portal pressure in hypertensive rats. J Hepatol 2000; 33: 733-737

Yokoyama Y, Wawrzyniak A, Baveja R, Sonin N, Clemens MG, Zhang JX. Altered endothelin receptor expression in prehepatic portal hypertension predisposes the liver to microcirculatory dysfunction in rats. J Hepatol 2001; 35: 29-36

Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. Hepatology 1991; 15: 323-328

Kavian I, Ohta M, Itani R, Sander F, Tarnawski AS, Sarfeh LJ. Tumor necrosis factor-alpha regulates inducible nitric oxide synthase gene expression in the portal hypertensive gastric mucosa of the rat. J Gastrointest Surg 1997; 1: 371-376

Muñoz J, Albillos A, Perez-Paramo M, Rossi I, Alvarez-Mon M. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Am J Physiol 1999; 276(3 Pt 1): G687-693

Tabrizchi R. The influence of tumour necrosis factor-alpha on the cardiovascular system of anaesthetized rats. Naunyn Schmiedebers Arch Pharmacol 2001; 363: 307-321

Zhang GL, Wang YH, Teng HL, Lin ZB. Effects of aminoguanidine on nitric oxide production induced by inflammatory cytokines and endotoxin in cultured rat hepatocytes. World J Gastroenterol 2001; 7: 331-334

Wiest R, Shah V, Sessa WC, Groszmann RJ. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999; 276(4 Pt 1): G1043-1051

Albomoz L, Bandi JC, de las Heras M, Mastai R, Decembré, an inhibitor of the expression of inducible nitric oxide synthase, does not modify the hyperdynamic state in cirrhotic rats. M edicina 2000; 60: 477-481

Chen YM, Qian ZM, Zhang J, Chang YZ, Duan XL. Distribution of constitutive nitric oxide synthase in the jejunum of adult rat. World J Gastroenterol 2002; 8: 537-539

Wolfaardt A, Kusaka Z, Szabo C, Belogh Z, Nagy S. Effects of selective nitric oxide synthase inhibition in hyperdynamic endotoxia in dogs. Eur Surg Res 1999; 31: 314-323

Paton T, Tazi KA, Sogni P, Keller J, Chagneau C, Poirel O, Philippe M, Moreau R, Lebrec D. Role of aortic nitric oxide synthase 3(eNOS) in the systemic vasodilation of portal hypertension. Gastroenterology 2000; 119: 196-200

Villa GL, Barletta G, Pantaleo P, Bene RD, Vizzutti F, Vecchiarini S, Masini E, Perfetto F, Tarquini R, Gentilini P, Laffi G. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001; 34: 19-27

Kojima H, Yamao J, Tsujimoto T, Uemura M, Takaoka A, Fukui H. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance. J Hepatol 2000; 32: 43-50

Kojima H, Sakurai S, Kuriyama S, Yoshii H, Imazu H, Uemura M, Nakatani Y, Yamao J, Fukui H. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo. J Hepatol 2001; 34: 805-811

Taddei S, Virdis A, Ghiadoni L, Salvetti A. Vascular effects of endothelin-1 in essential hypertension: relationship with cyclooxygenase-derived endothelium-dependent contracting factors and nitric oxide. J Cardiovasc Pharmacol 2000; 35(Suppl 2): S37-40

Poo JL, Jimenez W, Maria Munoz R, Bosch-Marce M, Bordas N, Morales-Ruis M, Perez M, Deulofeu R, Sale M, Arroyo V, Rodés J. Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects. Gastroenterology 1999; 116: 161-167

Varagic J, Jervis M, Jovic D, Nastic-Miric D, Adanaj-Grujic G, Markovic-Lipkovski J, Lackovic V, Radujkovic-Kuburovic G, Kentera D. Regional hemodynamics after chronic nitric oxide inhibition in spontaneously hypertensive rats. Am J Med Sci 2000; 320: 171-176

Edited by Wang XL and Zhu LH